Poor efficacy of amphotericin B-based therapy in CNS aspergillosis

Stefan Schwartz, Markus Ruhnke, Patricia Ribaud, Elizabeth Reed, Peter Troke, Eckhard Thiel

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Summary Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.

Original languageEnglish (US)
Pages (from-to)196-200
Number of pages5
JournalMycoses
Volume50
Issue number3
DOIs
StatePublished - May 1 2007

Fingerprint

Aspergillosis
aspergillosis
amphotericin B
Amphotericin B
central nervous system
Central Nervous System
therapeutics
Itraconazole
itraconazole
Neurosurgery
Flucytosine
Therapeutics
signs and symptoms (animals and humans)
Survival Rate
survival rate
Survival
Mortality

Keywords

  • Amphotericin B
  • Central nervous system aspergillosis
  • Itraconazole
  • Neuroaspergillosis

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Schwartz, S., Ruhnke, M., Ribaud, P., Reed, E., Troke, P., & Thiel, E. (2007). Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. Mycoses, 50(3), 196-200. https://doi.org/10.1111/j.1439-0507.2007.01345.x

Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. / Schwartz, Stefan; Ruhnke, Markus; Ribaud, Patricia; Reed, Elizabeth; Troke, Peter; Thiel, Eckhard.

In: Mycoses, Vol. 50, No. 3, 01.05.2007, p. 196-200.

Research output: Contribution to journalArticle

Schwartz, S, Ruhnke, M, Ribaud, P, Reed, E, Troke, P & Thiel, E 2007, 'Poor efficacy of amphotericin B-based therapy in CNS aspergillosis', Mycoses, vol. 50, no. 3, pp. 196-200. https://doi.org/10.1111/j.1439-0507.2007.01345.x
Schwartz, Stefan ; Ruhnke, Markus ; Ribaud, Patricia ; Reed, Elizabeth ; Troke, Peter ; Thiel, Eckhard. / Poor efficacy of amphotericin B-based therapy in CNS aspergillosis. In: Mycoses. 2007 ; Vol. 50, No. 3. pp. 196-200.
@article{1c1223c9ecb34b6aaf6273854f67bf64,
title = "Poor efficacy of amphotericin B-based therapy in CNS aspergillosis",
abstract = "Summary Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100{\%} with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.",
keywords = "Amphotericin B, Central nervous system aspergillosis, Itraconazole, Neuroaspergillosis",
author = "Stefan Schwartz and Markus Ruhnke and Patricia Ribaud and Elizabeth Reed and Peter Troke and Eckhard Thiel",
year = "2007",
month = "5",
day = "1",
doi = "10.1111/j.1439-0507.2007.01345.x",
language = "English (US)",
volume = "50",
pages = "196--200",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Poor efficacy of amphotericin B-based therapy in CNS aspergillosis

AU - Schwartz, Stefan

AU - Ruhnke, Markus

AU - Ribaud, Patricia

AU - Reed, Elizabeth

AU - Troke, Peter

AU - Thiel, Eckhard

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Summary Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.

AB - Summary Recently, improved response and survival rates in patients treated with voriconazole and neurosurgery for central nervous system (CNS) aspergillosis have been reported. We assessed retrospectively the outcome in 17 patients with definite or probable CNS aspergillosis treated with amphotericin B alone (n = 15) or in combination with 5-fluorocytosine (n = 3) or itraconazole (n = 2). Four patients underwent neurosurgery. The mortality rate was 100% with a median survival of only 10 days (range: 3-60) after onset of first symptoms or first radiological evidence of CNS aspergillosis. In conclusion, treatment with amphotericin B and itraconazole has negligible efficacy in CNS aspergillosis.

KW - Amphotericin B

KW - Central nervous system aspergillosis

KW - Itraconazole

KW - Neuroaspergillosis

UR - http://www.scopus.com/inward/record.url?scp=34247588706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247588706&partnerID=8YFLogxK

U2 - 10.1111/j.1439-0507.2007.01345.x

DO - 10.1111/j.1439-0507.2007.01345.x

M3 - Article

C2 - 17472616

AN - SCOPUS:34247588706

VL - 50

SP - 196

EP - 200

JO - Mycoses

JF - Mycoses

SN - 0933-7407

IS - 3

ER -